IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowe...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2019-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2751 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043024881483776 |
|---|---|
| author | E. L. Nasonov T. V. Korotaeva T. V. Dubinina A. M. Lila |
| author_facet | E. L. Nasonov T. V. Korotaeva T. V. Dubinina A. M. Lila |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel diseases, etc. This has served as an incentive to design new biological agents and small molecules, the main mechanism of action of which is based on blocking the pathological effects of interleukin-17 (IL-17), others are associated with the activation of Th17 cells cytokines or signaling pathways that regulate the effects of these cytokines. The review discusses current ideas about the mechanisms regulating the formation and functional activity of IL-17 family cytokines, as well as evidence for the importance of these cytokines in the pathogenesis of IID. |
| format | Article |
| id | doaj-art-f28a91d397ee4a91971d64c35dedbc55 |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2019-09-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-f28a91d397ee4a91971d64c35dedbc552025-08-20T02:55:20ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-09-0157440040610.14412/1995-4484-2019-400-4062510IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONSE. L. Nasonov0T. V. Korotaeva1T. V. Dubinina2A. M. Lila3V.A. Nasonova Research Institute of Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, Department of Rheumatology, Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRecently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel diseases, etc. This has served as an incentive to design new biological agents and small molecules, the main mechanism of action of which is based on blocking the pathological effects of interleukin-17 (IL-17), others are associated with the activation of Th17 cells cytokines or signaling pathways that regulate the effects of these cytokines. The review discusses current ideas about the mechanisms regulating the formation and functional activity of IL-17 family cytokines, as well as evidence for the importance of these cytokines in the pathogenesis of IID.https://rsp.mediar-press.net/rsp/article/view/2751il-23/il-17 axispsoriasispsoriatic arthritisankylosing spondylitisrheumatoid arthritisbiological agents |
| spellingShingle | E. L. Nasonov T. V. Korotaeva T. V. Dubinina A. M. Lila IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS Научно-практическая ревматология il-23/il-17 axis psoriasis psoriatic arthritis ankylosing spondylitis rheumatoid arthritis biological agents |
| title | IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS |
| title_full | IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS |
| title_fullStr | IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS |
| title_full_unstemmed | IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS |
| title_short | IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS |
| title_sort | il 23 il 17 inhibitors in immunoinflammatory rheumatic diseases new horizons |
| topic | il-23/il-17 axis psoriasis psoriatic arthritis ankylosing spondylitis rheumatoid arthritis biological agents |
| url | https://rsp.mediar-press.net/rsp/article/view/2751 |
| work_keys_str_mv | AT elnasonov il23il17inhibitorsinimmunoinflammatoryrheumaticdiseasesnewhorizons AT tvkorotaeva il23il17inhibitorsinimmunoinflammatoryrheumaticdiseasesnewhorizons AT tvdubinina il23il17inhibitorsinimmunoinflammatoryrheumaticdiseasesnewhorizons AT amlila il23il17inhibitorsinimmunoinflammatoryrheumaticdiseasesnewhorizons |